United States Drug Patent 8,268,791: Claim Scope, Expiration Risk, Orange Book Status, and Competitive Landscape

United States Patent No. 8,268,791 protects pharmaceutical compositions combining a triptan migraine drug with a maltose-based alkylglycoside absorption enhancer. The core scope is a triptan selected from six named active ingredients and an alkylglycoside containing a C12-C16 alkyl chain linked to maltose, at 0.05% to 20% by weight.

The patent is composition-focused. It does not, on the supplied claim language, independently claim a particular nasal device, dosage regimen, disease-treatment method, manufacturing process, or finished drug product. Its commercial value therefore depends on whether a competing product uses the claimed enhancer chemistry and concentration, rather than merely whether it contains a covered triptan.

What does United States Patent 8,268,791 protect?

Claim 1 contains four material limitations:

A pharmaceutical composition.
A triptan analog selected from:
- sumatriptan
- naratriptan
- zolmitriptan
- eletriptan
- almotriptan
- frovatriptan
An absorption-increasing amount of an alkylglycoside.
An alkylglycoside consisting of maltose linked to an alkyl chain containing 12 to 16 carbon atoms, present at 0.05% to 20% by weight.

The claim does not require one specific dosage form. On its face, the language could reach liquid, semisolid, powder, or other pharmaceutical compositions if the accused product satisfies the composition and concentration limitations. Infringement would still depend on claim construction, the patent specification, prosecution history, and the physical composition of the accused product.

Core claim limitations

Limitation	Scope
Triptan	Six listed triptans
Enhancer class	Alkylglycoside
Sugar component	Maltose
Alkyl chain	12 to 16 carbon atoms
Concentration	0.05% to 20% by weight
Functional property	Must be present in an absorption-increasing amount
Claimed subject	Pharmaceutical composition

The claim is narrower than a generic “triptan plus surfactant” claim. It requires a particular sugar headgroup, a defined carbon-chain range, and a substantial concentration window.

How do claims 2 through 15 narrow the patent scope?

Claims 2 through 15 create species claims around the broad genus in claim 1.

Claim	Subject matter
2	Sumatriptan
3	Dodecyl, tridecyl, or tetradecyl maltoside
4	Tetradecyl-beta-D-maltoside
5	Dodecyl-beta-D-maltoside
6	Tridecyl-beta-D-maltoside
7	Sumatriptan
8	Naratriptan
9	Zolmitriptan
10	Eletriptan
11	Almotriptan
12	Frovatriptan
13	Dodecyl maltoside plus sumatriptan
14	Composition also containing EDTA
15	Alkylglycoside is a beta anomer

Claims 2 and 7 appear substantively duplicative because both specify sumatriptan. Their legal effect depends on the exact issued patent record and prosecution history. The duplication does not expand the technical subject matter beyond sumatriptan compositions otherwise covered by claim 1.

Claim 13 is commercially important because it combines the most specific named active ingredient and enhancer pairing in the claim set: sumatriptan with dodecyl maltoside.

What formulations are protected by US 8,268,791?

The patent most directly covers formulations using one of three named maltosides:

Dodecyl maltoside, generally associated with a C12 alkyl chain.
Tridecyl maltoside, generally associated with a C13 alkyl chain.
Tetradecyl maltoside, generally associated with a C14 alkyl chain.

Claim 1 also reaches alkylglycosides containing C15 or C16 chains if they satisfy the maltose-linkage requirement and the other limitations. The dependent claims do not list those compounds, but a dependent claim is narrower than its parent and does not eliminate subject matter remaining in the independent claim.

What is excluded from the literal composition scope?

The supplied claims do not expressly cover:

Glucose-based alkylglycosides without maltose.
Alkylglycosides with alkyl chains shorter than C12 or longer than C16.
Non-glycosidic surfactants.
Maltose compositions below 0.05% or above 20% by weight.
Triptans not listed in claim 1.
A triptan-only formulation without the required alkylglycoside.
A formulation using a chemically different absorption enhancer.
A process for manufacturing the composition.
A method of treating migraine, unless a separate unprovided claim covers that subject matter.

The phrase “absorption increasing amount” introduces a functional limitation. A product may contain a qualifying alkylglycoside within the numerical concentration range but still present a dispute over whether the quantity increases absorption in the sense required by the claim.

How strong is the patent estate for the claimed triptan formulations?

The supplied claim set provides moderate composition-level coverage but does not, by itself, establish a broad patent estate around a commercial product.

Strengths

The patent has several features that can support enforcement:

Claim 1 covers six commercially recognized triptans.
The enhancer class is chemically defined.
The C12-C16 chain range creates a measurable structural boundary.
The 0.05%-20% concentration range is broad.
Claims 4, 5, 6, 13, and 15 provide narrower species positions for litigation.
Claim 14 adds an EDTA-containing formulation position.

Limitations

The claim set also has material limitations:

It is limited to maltose-based alkylglycosides.
It does not expressly claim a delivery device.
It does not identify a particular nasal, oral, buccal, pulmonary, or injectable route in the supplied language.
It does not claim a specific pharmacokinetic result.
It does not establish protection for all formulations of the six triptans.
It does not cover alternative absorption enhancers.
The “absorption increasing amount” limitation may require technical evidence.

A competitor could seek design-around protection by changing the sugar moiety, using an alkyl chain outside the claimed range, selecting a non-glycosidic enhancer, or using a concentration outside the claimed range, subject to potential doctrine-of-equivalents issues.

When does US 8,268,791 lose exclusivity?

A United States patent normally expires 20 years after the effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory modifications.[1] The grant date, September 18, 2012, does not itself determine the expiration date.

The controlling diligence points are:

Term issue	Relevance
Earliest effective nonprovisional filing date	Establishes the baseline 20-year term
Patent-term adjustment	Can extend the term for USPTO delay
Patent-term extension	May apply only in limited FDA regulatory circumstances
Terminal disclaimer	Can shorten the enforceable term
Maintenance fees	Nonpayment can cause expiration before the nominal term
Reissue or disclaimer record	Can alter the operative claim set or term

The expiration date should be taken from the USPTO Patent Center record and the patent’s official continuity and term data, not inferred from the patent number. A patent-term calculation based only on the 2012 grant date would be legally unreliable.

What is the Orange Book status of US 8,268,791?

Patent 8,268,791 is not automatically an Orange Book patent merely because it covers a pharmaceutical composition. The FDA Orange Book lists patents submitted by the holder of an approved new drug application and accepted as meeting the statutory listing requirements.[2]

An Orange Book listing would generally require:

An approved NDA product that practices the patent.
Submission of the patent by the NDA holder or authorized party.
FDA acceptance of the patent information.
A valid relationship between the patent claims and the approved drug product.

The supplied claim language does not identify an approved product, NDA number, NDA holder, or Orange Book listing. The existence of sumatriptan and other triptans in approved products does not establish that those products practice this patent.

Practical Orange Book consequence

If the patent is not listed against an approved NDA, a generic applicant generally would not use a Paragraph IV certification against this patent through the ordinary Orange Book pathway. The patent holder could still assert the patent in district court if it has standing and an infringing commercial product exists, but the statutory automatic-stay mechanism associated with an Orange Book Paragraph IV notice would not arise solely from the patent’s existence.

Which companies could challenge the patent through Paragraph IV?

A Paragraph IV challenge is available only when a patent is listed in the Orange Book for the relevant NDA and a generic applicant files an ANDA referencing that product.[3]

The relevant potential challengers would be companies developing:

A generic triptan formulation that uses dodecyl maltoside.
A generic nasal or transmucosal sumatriptan product containing a covered maltoside.
A product seeking approval for a listed formulation that the applicant believes does not infringe.
A product relying on invalidity, noninfringement, unenforceability, or improper-listing arguments.

The six active ingredients have different market histories and reference products. A Paragraph IV strategy would therefore be product-specific. A generic sumatriptan tablet would not ordinarily implicate these claims because the claims require the maltose-based alkylglycoside. A generic sumatriptan product containing a different formulation technology would present a materially different risk profile.

What patent litigation affects US 8,268,791?

The supplied information does not establish an asserted case, district court docket, Federal Circuit appeal, inter partes review, post-grant review, or settlement agreement involving Patent 8,268,791.

For freedom-to-operate analysis, litigation should be evaluated across four levels:

Infringement

The principal question is whether the accused formulation contains:

One of the six claimed triptans.
A maltose-linked alkyl chain within C12-C16.
The enhancer at 0.05%-20% by weight.
A quantity that qualifies as absorption-increasing.

Validity

Potential validity issues may include:

Anticipation by prior triptan formulations.
Obviousness based on known alkylglycoside absorption enhancers.
Written-description support for the full six-drug and C12-C16 scope.
Enablement across the full concentration range and all claimed triptans.
Indefiniteness involving “absorption increasing amount.”

Claim construction

Key construction disputes may concern:

The meaning of “alkylglycoside.”
Whether “maltose linked by glycosidic linkage” requires a particular anomer or linkage position.
Whether “between 12 to 16 carbons” is inclusive.
Whether the concentration is calculated on a weight/weight basis for the whole composition.
The evidentiary standard for “absorption increasing amount.”

Remedies

For an approved pharmaceutical product, the available remedies may include injunctive relief, damages, a reasonable royalty, and, in appropriate cases, enhanced damages. The practical remedy depends on patent enforceability, market entry timing, product substitution, and the availability of a noninfringing formulation.

Does the patent create biosimilar risk?

No conventional biosimilar pathway applies. The claimed products contain small-molecule triptans, including sumatriptan, naratriptan, zolmitriptan, eletriptan, almotriptan, and frovatriptan. These are not biologic active ingredients regulated through the abbreviated biologics license application pathway under the Public Health Service Act.[4]

The relevant competitive pathways are:

ANDA approval for a generic small-molecule product.
NDA or 505(b)(2) approval for a reformulated or differently delivered product.
Commercial launch after patent expiration, invalidation, or a license.
Noninfringing formulation development.

Biosimilar interchangeability, reference biologic exclusivity, and biologic patent dance issues are not central to this patent.

How does this patent compare with competing triptan patent strategies?

The patent occupies a narrower and more specialized position than basic active-ingredient patents.

Patent strategy	Typical scope	Relevance to US 8,268,791
Active-ingredient patent	Chemical compound	Usually expired for the listed triptans
Salt or polymorph patent	Solid-state form	Not covered by supplied claims
Formulation patent	Composition and excipients	Directly relevant
Delivery-device patent	Device and administration system	Not covered by supplied claims
Method-of-use patent	Dosing or treatment method	Not covered by supplied claims
Manufacturing patent	Synthesis or processing	Not covered by supplied claims
Combination patent	Active ingredient plus enhancer	Core category of US 8,268,791

The patent is strongest against a product that copies the claimed enhancer platform. It is weaker against products that deliver the same triptan through a different formulation architecture.

What generic launch scenarios exist?

Scenario 1: Generic triptan without maltose alkylglycoside

A conventional tablet, capsule, or noncovered nasal formulation generally presents low literal infringement risk under the supplied claims.

Scenario 2: Generic product using a different enhancer

A competitor using a non-maltose surfactant or another absorption technology may avoid literal infringement, subject to equivalence arguments.

Scenario 3: Product using dodecyl maltoside

This presents the highest risk because claim 5 and claim 13 specifically identify dodecyl maltoside, and claim 13 also expressly covers the sumatriptan combination.

Scenario 4: Product using tetradecyl maltoside

This presents substantial risk under claim 4 and the broader composition claim.

Scenario 5: Product using a C15 or C16 maltose alkylglycoside

The dependent claims do not expressly name these species, but claim 1 may reach them if the compound satisfies the maltose-linkage and concentration limitations.

Scenario 6: Concentration outside the claimed range

A formulation below 0.05% or above 20% may avoid literal infringement of claim 1, although formulation performance, measurement methodology, and equivalents could become disputed issues.

What manufacturing and intellectual-property barriers remain?

The main barrier is not the triptan active ingredient. The listed triptans are established small molecules with extensive generic competition. The technical barrier is reproducing absorption enhancement while maintaining pharmaceutical stability, tolerability, manufacturability, and regulatory consistency.

A product developer would need to assess:

Supplier availability for pharmaceutical-grade maltosides.
Control of alkyl-chain distribution and impurity profile.
Anomeric composition and linkage characterization.
Assay methodology for enhancer concentration.
Stability of the triptan-enhancer combination.
Local tolerability and irritation.
Device compatibility for nasal or transmucosal delivery.
Bioavailability and pharmacokinetic comparability.
Whether EDTA is present.
Whether the final composition practices any additional formulation patents.

A supplier change could create patent and regulatory differences even when the active ingredient remains identical.

What is the commercial exposure?

The patent does not cover the entire triptan market. Its revenue exposure is limited to products that combine a listed triptan with the claimed maltose alkylglycoside technology.

The greatest commercial sensitivity would arise from:

A sumatriptan product using dodecyl maltoside.
A fast-acting nasal or transmucosal product using tetradecyl maltoside.
A reformulated triptan product relying on absorption enhancement to differentiate from generic oral tablets.
A product protected by related device, method-of-use, or manufacturing patents.

Conventional oral sumatriptan, naratriptan, zolmitriptan, eletriptan, almotriptan, and frovatriptan products do not become high-risk merely because the active ingredient appears in claim 1.

Key Takeaways

US 8,268,791 is a composition patent covering six triptans combined with maltose-linked C12-C16 alkylglycosides.
The claimed concentration is 0.05% to 20% by weight.
Dodecyl, tridecyl, and tetradecyl maltoside are expressly identified in dependent claims.
Sumatriptan plus dodecyl maltoside has the clearest species-level exposure through claim 13.
EDTA and beta-anomer limitations create narrower fallback positions.
The patent does not, on the supplied claim language, independently claim a device, route, treatment method, manufacturing process, or pharmacokinetic result.
It is a small-molecule formulation patent, so biosimilar risk is not applicable.
Paragraph IV exposure depends on an accepted Orange Book listing against a relevant approved NDA.
Patent expiration cannot be determined from the 2012 grant date alone. The effective filing date, patent-term adjustment, terminal disclaimer, maintenance record, and any extension must control.
The principal design-around routes are changing the enhancer chemistry, sugar moiety, carbon-chain length, concentration, or delivery architecture.

FAQs

Does US 8,268,791 cover ordinary sumatriptan tablets?

Not necessarily. The claims require a maltose-linked C12-C16 alkylglycoside at 0.05%-20% by weight. A standard sumatriptan tablet without that enhancer would generally fall outside the supplied claim language.

Is tetradecyl maltoside the same as tetradecyl-beta-D-maltoside?

Tetradecyl-beta-D-maltoside is a specific beta-D anomeric form. Claim 4 expressly identifies that species, while claim 3 uses the broader term tetradecyl maltoside.

Can a competitor avoid the patent by using a C11 alkylglycoside?

A C11 alkylglycoside would fall outside the literal C12-C16 range in claim 1, assuming the carbon count and chemical identity are established. The doctrine of equivalents could still become relevant in litigation.

Does adding EDTA create a separate patent risk?

Yes. Claim 14 adds EDTA to the claimed composition. A product that satisfies claim 1 and also contains EDTA may fall within the narrower EDTA claim, although EDTA alone does not create infringement if the other limitations are absent.

Does FDA approval prove that a product infringes this patent?

No. FDA approval addresses safety, efficacy, quality, and regulatory requirements. Patent infringement depends on the asserted claims and the composition, process, or conduct at issue. An FDA-approved product may avoid the patent, infringe it, or require a license.

References

United States Patent and Trademark Office. (2024). Patent term adjustment and patent term extension provisions. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Code, 21 U.S.C. § 355(j).
U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products.
United States Patent and Trademark Office. (2012). U.S. Patent No. 8,268,791.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Tonix Meds	TOSYMRA	sumatriptan	SPRAY;NASAL	210884-001	Jan 25, 2019		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3678649	⤷ Start Trial	301317	Netherlands	⤷ Start Trial
European Patent Office	3678649	⤷ Start Trial	CA 2025 00007	Denmark	⤷ Start Trial
European Patent Office	3678649	⤷ Start Trial	PA2025507	Lithuania	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 8,268,791